Drug intelligence / Profile preview

sacchachitin

Development stage: Phase 2
Lead developer: National Council of Science
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

Sacchachitin is a novel chitin-polysaccharide conjugate macromolecule derived from the extraction residue of Ganoderma fruiting bodies, particularly Ganoderma tsugae and Ganoderma lucidum. It is obtained by processing the residue through digestion with KOH and bleaching with NaClO, resulting in a water-insoluble material. Sacchachitin has demonstrated potential for enhancing wound healing by promoting cell proliferation and inhibiting proteolysis. It has been formulated in various forms including micronized sacchachitin (mSC) nanogel and TEMPO-oxidized sacchachitin nanofibers (TOSCNFs) for different therapeutic applications.

Other names: SACCHACHITIN

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on sacchachitin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacchachitin.

Explore the full profile